Teva Pharmaceutical Industries (TEVA) closed at $38.54 on November 19, 2026, down 8.7% from the previous close, on volume of 9,660,708 shares (30-day average 7,356,583).
Data as of November 19, 2026.
19-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Calendar Call Ladder | 18-Dec-2642 C|15-Jan-2744 : 49 C | 6,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Teva (TEVA) Receives a Buy from Leerink Partners
TipRanks (Fri, 20-Nov 6:56 AM ET)
Teva falls as R&D head exits amid shift to innovative medicines
Seeking Alpha News (Thu, 19-Nov 1:17 PM ET)
Barclays Sticks to Their Buy Rating for Teva (TEVA)
TipRanks (Thu, 19-Nov 5:06 AM ET)
Teva Announces R&D Chief Departure and Transition Leadership
TipRanks (Wed, 18-Nov 5:43 PM ET)
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
Globe Newswire (Wed, 18-Nov 5:00 PM ET)
Teva’s Igalmi Home-Use FDA Clearance Supports Buy Rating and $54 Price Target
TipRanks (Wed, 18-Nov 4:55 AM ET)
Glenview ups stakes in Meta, Teva; cuts CVS, Block in Q3; exits DKS, STM
Seeking Alpha News (Tue, 17-Nov 5:18 AM ET)
Einhorn's DME exits PayPal, Stubhub, adds Century Aluminum, among Q3 moves
Seeking Alpha News (Mon, 16-Nov 6:46 PM ET)
Teva Stock Slips as the Drugmaker Reaches a Settlement Agreement in a Price-Fixing Lawsuit
TipRanks (Mon, 16-Nov 12:48 PM ET)
Teva gains at-home indication for Igalmi for agitation with schizophrenia
Seeking Alpha News (Mon, 16-Nov 12:36 PM ET)
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Teva Pharmaceutical Industries trades on the NYSE stock market under the symbol TEVA.
As of November 19, 2026, TEVA stock price declined to $38.54 with 9,660,708 million shares trading.
TEVA has a beta of 1.11, meaning it tends to be more sensitive to market movements. TEVA has a correlation of 0.15 to the broad based SPY ETF.
TEVA has a market cap of $44.95 billion. This is considered a Large Cap stock.
Last quarter Teva Pharmaceutical Industries reported $4 billion in Revenue and $.86 earnings per share. This beat revenue expectation by $146 million and exceeded earnings estimates by $.14.
In the last 3 years, TEVA traded as high as $44.57 and as low as $9.04.
The top ETF exchange traded funds that TEVA belongs to (by Net Assets): IEFA, EFA, EIS, IXUS, EFG.
TEVA has outperformed the market in the last year with a return of +57.7%, while the SPY ETF gained +9.2%. In the last 3 month period, TEVA beat the market returning +2.9%, while SPY returned -6.7%. However, in the most recent 2 weeks TEVA has underperformed the stock market by returning -7.8%, while SPY returned -2.3%.
TEVA support price is $41.25 and resistance is $43.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TEVA shares will trade within this expected range on the day.